# Efficient Brain Delivery of Neuroprotective TrkB Agonist Antibodies in Alzheimer’s Disease Using CD98hc Bispecific Shuttles > **NIH NIH F32** · UNIVERSITY OF MICHIGAN AT ANN ARBOR · 2022 · $67,174 ## Abstract Alzheimer’s disease (AD) is the most common age-related neurodegenerative disease. Despite the great potential of biologics (e.g., therapeutic antibodies) to affect AD pathophysiology, these agents are generally unable to penetrate the blood-brain barrier (BBB), which represents their biggest hurdle to clinical efficacy. One promising strategy is to use bispecific antibody BBB shuttles, which involve fusing IgGs to a second affinity ligand that engages a cerebrovascular endothelial target and induces transport across the BBB. While most previous work has focused on BBB shuttles that target transferrin receptor (TfR-1), my lab has developed a BBB shuttle that engages CD98hc, the heavy chain of the large neutral amino acid transporter (LAT-1). Notably, our preliminary data demonstrate superior brain parenchymal delivery and retention of IgGs shuttled via CD98hc as compared to those shuttled via TfR-1. Importantly, this first-generation CD98hc shuttle enables brain delivery of off-the-shelf IgGs simply by attaching a single-chain CD98hc antibody to the C-terminus of one of the two IgG heavy chains. The objectives of this proposal are twofold: i) to define the optimal CD98hc shuttle characteristics (CD98hc single-chain affinity, valency, and epitope) for maximal brain parenchymal delivery and retention to guide the design of second-generation CD98hc shuttles; and ii) to generate proof-of-concept efficacy data in an AD mouse model (tau, PS19) using a TrkB agonist antibody that induces neuroprotective signaling. For the first objective, I hypothesize that BBB shuttles with monovalent CD98hc single-chain antibodies (as used in the first- generation shuttle) and reduced CD98hc single-chain antibody affinity (relative to the first-generation shuttle) will maximize antibody concentrations in the brain parenchyma by improving antibody dissociation at the abluminal side of the brain endothelium, as observed for TfR-1 shuttles. For the second objective, I hypothesize that CD98hc shuttles that deliver TrkB agonist IgGs to the brain parenchyma of tau transgenic mice will reduce neuronal and synaptic loss and cognitive deficits. This hypothesis is supported by the partial efficacy of non- shuttled TrkB antibodies delivered systemically and high efficacy of viral brain delivery of the TrkB ligand in AD mouse models. Therefore, I propose in Aim 1 to develop an optimized second-generation CD98hc shuttle by evaluating the impact of CD98hc single-chain antibody affinity, valency, and epitope on antibody concentrations in the mouse brain parenchyma as a function of time. Next, in Aim 2, I propose to evaluate the ability of a first- generation CD98hc shuttle to deliver a TrkB agonist IgG to the brain parenchyma, to activate TrkB in wild-type and tau (PS19) transgenic mice, and to mediate neuroprotection in tau transgenic mice. A key expected outcome is the development of an optimized CD98hc shuttle that can be used to deliver a wide range of existing therapeutic antibo... ## Key facts - **NIH application ID:** 10537474 - **Project number:** 1F32AG079576-01 - **Recipient organization:** UNIVERSITY OF MICHIGAN AT ANN ARBOR - **Principal Investigator:** Michael John Lucas - **Activity code:** F32 (R01, R21, SBIR, etc.) - **Funding institute:** NIH - **Fiscal year:** 2022 - **Award amount:** $67,174 - **Award type:** 1 - **Project period:** 2022-08-01 → 2024-07-31 ## Primary source NIH RePORTER: https://reporter.nih.gov/project-details/10537474 ## Citation > US National Institutes of Health, RePORTER application 10537474, Efficient Brain Delivery of Neuroprotective TrkB Agonist Antibodies in Alzheimer’s Disease Using CD98hc Bispecific Shuttles (1F32AG079576-01). Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/grant/nih/10537474. Licensed CC0. --- *[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*